Key result
Proxied therapeutic inhibition of sclerostin linked to ~35% higher AF risk.
Why the study?
Large-scale randomized controlled trials have reported conflicting findings regarding the cardiovascular effects of pharmacological sclerostin inhibition.
Does proxied therapeutic inhibition of sclerostin increase the risk of atrial fibrillation?
Observational (n=1,030,836)
Mendelian randomization
Does proxied therapeutic inhibition of sclerostin increase the risk of atrial fibrillation?
Effect estimate: OR 1.353 (95% CI 1.077-1.701)
p-value: p=0.009
Mendelian randomization suggests that therapeutic inhibition of sclerostin may increase the risk of atrial fibrillation, highlighting a potential cardiovascular safety concern for SOST inhibitors.
Genetic proxies for SOST inhibition associate with higher AF risk; leaves open whether approved therapies confer similar effects.
Pharmacological inhibition of sclerostin (SOST) is clinically applied to treat osteoporosis. However, large-scale randomized controlled trials have reported conflicting findings regarding the cardiovascular effects of SOST inhibition. This study aimed to evaluate whether sustained SOST inhibition, mimicked by instrumental genetic variants, is associated with the altered risk of cardiovascular diseases (CVDs). The individual-level genomic data were obtained from the UK Biobank, including 377,585 participants in the genome wide association study (GWAS) for estimated heel bone mineral density (eBMD). Summary-level genetic data for CVDs were retrieved from publicly available GWASs, with sample sizes ranging from 332,477 to 1,030,836 participants. The conditional quantile-quantile (QQ) plot was used to visualize the genetic pleiotropy between circulating SOST, eBMD and CVDs. By integrating genetic, transcriptomic, and proteomic data, Mendelian randomization was performed to assess the relationship between exposures and CVDs. We observed polygenic overlap between circulating SOST and eBMD as well as atrial fibrillation (AF). Trans-protein quantitative trait loci (pQTLs) around the B4GALNT3 gene, instead of the genetic variants across the genome, could be instrumental variables to proxy the therapeutic effect of SOST inhibition. Further, increasing level of B4GALNT3 gene expression in several tissues was associated with a decreased level of circulating SOST. Consistently, in vitro evidence validated that B4GALNT3 overexpression significantly decreased SOST protein secretion. Notably, increasing level of B4GALNT3 gene expression in the same tissues was also associated with increased eBMD and higher risk of AF. The proxied SOST inhibition (instrumented by B4GALNT3 genetic variants) had a significant causal effect on increased eBMD (β-coefficient=0.034, SE = 0.007, P = 2.81 × 10 −7 ) and increased risk of AF (OR = 1.353, 95%CI = 1.077–1.701, P = 0.009). The results were replicated in the MR analyses with different instrumental variables based on different linkage disequilibrium (LD) thresholds. This multi-omics study suggested that reduced circulating SOST was associated with an increased risk of AF, which warrants attention in patients undergoing SOST inhibition treatment.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2026) conducted an observational in Osteoporosis and Atrial Fibrillation (n=1,030,836). Proxied therapeutic inhibition of sclerostin (SOST) vs. Genetic baseline was evaluated on Risk of atrial fibrillation (AF) (OR 1.353, 95% CI 1.077-1.701, p=0.009). Proxied therapeutic inhibition of sclerostin, instrumented by B4GALNT3 genetic variants, was associated with an increased risk of atrial fibrillation (OR 1.353).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: